A study evaluating regorafenib following completion of standard chemotherapy for patients with colon cancer

What we are studying

This study has two study groups (Arm 1 and Arm 2). Patients in Arm 1 will take 3 placebo tablets by mouth. Patients in Arm 2 will take 3 regorafenib tablets by mouth. The regorafenib and placebo tablets look the same. Neither the study participant, their doctor, nor the study team will know whether the study participant is taking placebo or regorafenib. Study participants will be randomized to either Arm 1 or Arm 2. Randomized means that a computer will, by chance, assign them to either Arm 1 or Arm 2 of the study (like flipping a coin). Half of the patients joining this study will be assigned to Arm 1; the other half of patients will be assigned to Arm 2. This is done because no one knows if taking regorafenib after adjuvant chemotherapy is better or worse than no further therapy.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18 - 80

Eligibility Criteria

  • Must have completed at least 4 months of adjuvant chemotherapy

What is involved

  • Study participants will be asked to take regorafenib/placebo
  • 3 tablets once a day
  • For 21 days followed by 7 days of no regorafenib/placebo for up to 2 years as long as the study participant tolerates the drug


Parking will be validated for all study related visits.

Contact Information

Study Coordinator
Amy Neal

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.